VT-109

VT-109 is a novel, next-generation recombinant fusion protein designed to target and inhibit both B-cell activating factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), two members of the tumor necrosis factor ligand superfamily that play key roles in B cell survival, differentiation, and autoantibody production. Developed by Vera Therapeutics under license from Stanford University, VT-109 is engineered for enhanced potency, selectivity, or pharmacokinetic properties compared to earlier dual BAFF/APRIL inhibitors. Its primary mechanism involves blocking the activity of BAFF and APRIL to modulate B cell function in immunological diseases. Preclinical studies suggest broad therapeutic potential across a spectrum of B cell-mediated disorders[1][3][4][8][9].

Other names

VT 109VT109VT-109